美国卫生系统中原发性胆汁性胆管炎患病率与治疗的相关因素
基于FOLD联盟11个地理分布不同的卫生系统2003至2014年数据,用经验证电子健康记录分类模型识别出4241例原发性胆汁性胆管炎(PBC)患者,估算12年患病率为29.3/10万,女性、白人及60-70岁人群患病率最高,男性和非裔美国人患病率较低且接受熊去氧胆酸治疗的可能性更低。
要点
- PBC估计12年患病率为29.3/10万,女性42.8/10万、白人29.6/10万、60-70岁44.7/10万,均高于对应参考组。
- 男性患病率10.7/10万、非裔美国人19.7/10万,分别低于女性和白人。
- 男性与非裔美国人接受熊去氧胆酸治疗的比值比分别为0.6和0.5(P < .05)。
核心结论
- 在大量接受常规临床治疗的PBC患者队列中,观察到PBC患病率和治疗在不同性别、种族和年龄间存在显著差异。
研究设计与样本
- 分析FOLD联盟数据,该联盟来自11个地理分布不同的卫生系统。
- 开发并验证基于电子健康记录的分类模型,用于识别2003年至2014年FOLD数据库中的PBC患者。
- 采用多变量模型评估与PBC患病率及熊去氧胆酸(UDCA)治疗相关的因素。
主要发现
- 分类模型准确度优良,受试者工作特征曲线下面积为93%,灵敏度94%,特异度87%。
- 诊断时平均年龄60岁;21%为西班牙裔,8%为非裔美国人,7%为亚裔美国人/美洲印第安人/太平洋岛民。
- 49%的队列碱性磷酸酶水平升高,总体70%接受UDCA治疗。
- 估计12年PBC患病率为29.3/10万;调整后患病率在女性(42.8/10万)、白人患者(29.6/10万)和60-70岁患者(44.7/10万)中最高,男性和非裔美国人(分别为10.7/10万和19.7/10万)显著低于女性和白人;男性和非裔美国人接受UDCA治疗的比值比分别为0.6和0.5(P < .05)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Reported prevalence of primary biliary cholangitis (PBC) varies widely. Demographic features and treatment patterns are not well characterized in the United States (US). We analyzed data from the Fibrotic Liver Disease (FOLD) Consortium, drawn from 11 geographically diverse health systems, to investigate epidemiologic factors and treatment of PBC in the US. METHODS: We developed a validated electronic health record-based classification model to identify patients with PBC in the FOLD database from 2003 through 2014. We used multivariable modeling to assess the effects of factors associated with PBC prevalence and treatment with ursodeoxycholic acid (UDCA). RESULTS: We identified 4241 PBC cases among over 14.5 million patients in FOLD health systems; median follow-up was 5 years. Accuracy of the classification model was excellent, with an area under the receiver operating characteristic curve value of 93%, 94% sensitivity, and 87% specificity. The average patient age at diagnosis was 60 years; 21% were Hispanic, 8% were African American, and 7% were Asian American/American Indian/Pacific Islander. Half of the cohort (49%) had elevated levels of alkaline phosphatase, and overall, 70% were treated with UDCA. The estimated 12-year prevalence of PBC was 29.3 per 100,000 persons. Adjusted prevalence values were highest among women (42.8 per 100,000), White patients (29.6 per 100,000), and patients 60-70 years old (44.7 per 100,000). Prevalence was significantly lower among men and African Americans (10.7 and 19.7 per 100,000, respectively) than women and whites; men and African Americans were also less likely to receive UDCA treatment (odds ratios, 0.6 and 0.5, respectively; P < .05). CONCLUSIONS: In an analysis of a large cohort of patients with PBC receiving routine clinical care, we observed significant differences in PBC prevalence and treatment by gender, race, and age.
引用
- Lu M, Li J, Haller IV, et al. Factors Associated With Prevalence and Treatment of Primary Biliary Cholangitis in United States Health Systems. Clin Gastroenterol Hepatol. 2017. PMID: 29066370. doi:10.1016/j.cgh.2017.10.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。